| The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients V Haufroid, M Mourad, V Van Kerckhove, J Wawrzyniak, M De Meyer, ... Pharmacogenetics and Genomics 14 (3), 147-154, 2004 | 563 | 2004 |
| Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference P Wallemacq, VW Armstrong, M Brunet, V Haufroid, DW Holt, A Johnston, ... Therapeutic drug monitoring 31 (2), 139-152, 2009 | 546 | 2009 |
| Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report M Brunet, T Van Gelder, A Åsberg, V Haufroid, DA Hesselink, L Langman, ... Therapeutic drug monitoring 41 (3), 261-307, 2019 | 506 | 2019 |
| Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock FS Taccone, PF Laterre, T Dugernier, H Spapen, I Delattre, X Wittebole, ... Critical care 14, 1-9, 2010 | 458 | 2010 |
| Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. M Buysschaert, AS Dramais, PE Wallemacq, MP Hermans Diabetes care 23 (12), 1816-1822, 2000 | 367 | 2000 |
| Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil M Mourad, J Malaise, D Chaib Eddour, M De Meyer, J Konig, R Schepers, ... Clinical chemistry 47 (1), 88-94, 2001 | 246 | 2001 |
| Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock FS Taccone, PF Laterre, H Spapen, T Dugernier, I Delattre, B Layeux, ... Critical care 14, 1-10, 2010 | 243 | 2010 |
| CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study V Haufroid, P Wallemacq, V VanKerckhove, L Elens, M De Meyer, ... American journal of transplantation 6 (11), 2706-2713, 2006 | 221 | 2006 |
| FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects PE Wallemacq, R Reding Clinical chemistry 39 (11), 2219-2228, 1993 | 210 | 1993 |
| Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension E Berra, M Azizi, A Capron, A Høieggen, F Rabbia, SE Kjeldsen, ... Hypertension 68 (2), 297-306, 2016 | 201 | 2016 |
| Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients L Elens, RH Van Schaik, N Panin, M De Meyer, P Wallemacq, D Lison, ... Pharmacogenomics 12 (10), 1383-1396, 2011 | 200 | 2011 |
| Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients PE Wallemacq, RK Verbeeck Clinical pharmacokinetics 40, 283-295, 2001 | 198 | 2001 |
| Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients … EM Sokal, H Antunes, C Beguin, M Bodeus, P Wallemacq, JV de Goyet, ... Transplantation 64 (10), 1438-1442, 1997 | 196 | 1997 |
| Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban J Douxfils, A Tamigniau, B Chatelain, C Chatelain, P Wallemacq, ... Thrombosis and haemostasis 110 (10), 723-731, 2013 | 179 | 2013 |
| Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis M Meyer, F Huaux, X Gavilanes, S Van Den Brûle, P Lebecque, S Lo Re, ... American journal of respiratory cell and molecular biology 41 (5), 590-602, 2009 | 156 | 2009 |
| CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation A Capron, M Mourad, M De Meyer, L De Pauw, DC Eddour, D Latinne, ... Pharmacogenomics 11 (5), 703-714, 2010 | 148 | 2010 |
| Therapeutic drug monitoring of everolimus: a consensus report M Shipkova, DA Hesselink, DW Holt, EM Billaud, T Van Gelder, ... Therapeutic drug monitoring 38 (2), 143-169, 2016 | 141 | 2016 |
| Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids M Mourad, G Mourad, P Wallemacq, V Garrigue, C Van Bellingen, ... Transplantation 80 (7), 977-984, 2005 | 138 | 2005 |
| Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation M Mourad, J Malaise, D Chaib Eddour, M De Meyer, J Konig, R Schepers, ... Clinical chemistry 47 (7), 1241-1248, 2001 | 133 | 2001 |
| Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice R Legssyer, F Huaux, J Lebacq, M Delos, E Marbaix, P Lebecque, ... Respiratory research 7, 1-13, 2006 | 132 | 2006 |
